Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Auditor change
Consulting agrmnt
Quarterly results
Appointed director
Stock private placement
Asset disposition
Acq. announced
TearLab Corp (TEAR) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/09/2020 8-K Quarterly results
05/29/2020 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Consent"
05/13/2020 8-K Quarterly results
05/12/2020 8-K Quarterly results
05/11/2020 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Paycheck Protection Program Promissory Note and Agreement"
05/11/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
04/21/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/05/2020 8-K Quarterly results
11/08/2019 8-K Quarterly results
Docs: "TearLab Corporation Reports Third Quarter 2019 Financial Results"
10/08/2019 8-K Quarterly results
08/08/2019 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "TearLab Corporation Reports Second Quarter and First Half 2019 Financial Results"
05/09/2019 8-K Quarterly results
Docs: "TearLab Corporation Reports First Quarter 2019 Financial Results"
03/21/2019 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "TearLab Corporation Reports Fourth Quarter and Full Year 2018 Financial Results"
02/01/2019 8-K Quarterly results
11/13/2018 8-K Entry into a Material Definitive Agreement
10/10/2018 8-K Other Events, Financial Statements and Exhibits
08/13/2018 8-K Entry into a Material Definitive Agreement
08/09/2018 8-K Quarterly results
Docs: "TearLab Corporation Reports Second Quarter and First Half 2018 Financial Results SAN DIEGO, Aug 9, 2018 — TearLab Corporation today reported its consolidated financial results for the second quarter ended June 30, 2018. All dollar amounts are expressed in U.S. currency and results are reported in accordance with United States generally accepted accounting principles except where noted otherwise. Second Quarter and Recent Highlights - Second quarter revenue of $6.4 million, holding revenue flat over the first quarter of 2018 - Income from operations of $0.5 million, compared to operating loss of $2.8 million in second quarter 2017 - Expanded the U.S. active device base to 4,761 TearLab Osmolarity Systems - On track for resubmission and U.S. Food and Drug Administration response to 510 fili..."
08/03/2018 8-K Other Events
06/22/2018 8-K Submission of Matters to a Vote of Security Holders
05/03/2018 8-K Entry into a Material Definitive Agreement
04/05/2018 8-K Entry into a Material Definitive Agreement
03/02/2018 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "TearLab Corporation Reports Fourth Quarter and Full Year 2017 Financial Results SAN DIEGO, March 2, 2018 — TearLab Corporation today reported its consolidated financial results for the fourth quarter and twelve months ended December 31, 2017. All dollar amounts are expressed in U.S. currency and results are reported in accordance with United States generally accepted accounting principles except where noted otherwise. Recent Highlights - Grew quarterly revenue sequentially to $6.9 million, a $0.4 million increase compared to the third quarter of 2017 - Reduced full year loss from operations by 26% compared to 2016, from $16.0 million to $11.8 million - Expanded the U.S. active device base to 4,623 TearLab Osmolarity Systems - Submitted a 510 application to the U.S. Food and Drug Administr..."
01/18/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/21/2017 8-K Cost Associated with Exit or Disposal Activities
11/13/2017 8-K Quarterly results
Docs: "TearLab Corporation Reports Third Quarter and September Year-To-Date 2017 Financial Results SAN DIEGO, November 13, 2017 — TearLab Corporation today reported its consolidated financial results for the third quarter and nine months ended September 30, 2017. All dollar amounts are expressed in U.S. currency and results are reported in accordance with United States generally accepted accounting principles except where noted otherwise. Third Quarter 2017 and Recent Operational Highlights - Announced updated U.S. regulatory strategy for TearLab Discovery™ System; Company remains on-track to submit 510 application to FDA by year-end - Expanded the active U.S. user base of TearLab Osmolarity Systems in key programs by 74 units to 4,522 devices - Further reduction in operating expenses; ope..."
11/09/2017 8-K Other Events, Financial Statements and Exhibits
Docs: "TearLab Corporation Begins Trading on OTCQB SAN DIEGO, November 9, 2017 -- TearLab Corporation , today announced that shares of its common stock will begin trading on the OTCQB Market, which is operated by OTC Markets Group Inc., effective with the open of business on November 9, 2017 under its current trading symbol “TEAR.” As previously disclosed, the Company was unable to regain compliance with NASDAQ Listing Rule 5550 prior to November 6, 2017 and as a result the Company received written notification from the NASDAQ’ s staff stating that the Company’ s Common Stock is subject to delisting from the NASDAQ Capital Market. The Company understands that its common stock will be formally delisted from NASDAQ as of the start of trading on November 9, 2017 via NASDAQ’ s filing of a Form 25 “N..."
11/07/2017 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
10/16/2017 8-K Quarterly results
08/14/2017 8-K Quarterly results
06/27/2017 8-K Form 8-K - Current report
05/15/2017 8-K Form 8-K - Current report
05/15/2017 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy